Foundayo Guide
Foundayo (orforglipron) is the first FDA-approved once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management. Approved by the FDA on April 1, 2026, Foundayo is taken as a single tablet once a day with no food or water restrictions, marking a major change from injectable GLP-1s and from oral semaglutide (Rybelsus), which has strict food and water rules. In the 72-week ATTAIN-1 phase 3 trial, the highest dose produced 12.4% mean weight loss versus 0.9% on placebo.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
At a Glance
| Generic Name | Orforglipron |
| Brand Names | Foundayo |
| FDA Status | FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Cannot be used with other GLP-1 receptor agonists.[1] |
| Approval Date | April 1, 2026[1] |
How Foundayo Works
Orforglipron is a non-peptide small molecule that binds and activates the GLP-1 receptor directly. Unlike injectable GLP-1 peptides (semaglutide, tirzepatide) or oral peptide formulations (Rybelsus), orforglipron is a true small organic molecule that survives stomach acid and digestion, eliminating the need for injection or special food restrictions. It produces the same downstream effects as injectable GLP-1 agonists: appetite suppression, slowed gastric emptying, and reduced food reward signaling.[2]
Dosing Schedule
Foundayo uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
Side Effects
Common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, hair loss. Serious: pancreatitis, dehydration leading to kidney problems, gallbladder disease, hypoglycemia (especially with insulin/sulfonylureas), serious allergic reactions, diabetic retinopathy progression in T2D patients, increased aspiration risk during anesthesia. Boxed warning: thyroid C-cell tumors observed in animal studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]
This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].
Clinical Trial Results
ATTAIN-1 (NCT05869903) was a 72-week phase 3 randomized placebo-controlled trial of 3,127 adults with obesity or overweight plus a weight-related comorbidity (no diabetes), conducted across 10 countries. Highest dose produced 12.4% mean body weight reduction (~27 lbs) versus 0.9% on placebo (efficacy estimand). Treatment-regimen estimand: 11.1% (~25 lbs) vs 2.1% placebo. Foundayo also reduced waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all doses. ATTAIN-2 in patients with type 2 diabetes is ongoing.[2]
Where to Get Foundayo
These telehealth providers offer access to orforglipron or compounded equivalents with online consultations and home delivery.
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded orforglipron from licensed 503A and 503B pharmacies is legal under federal compounding law[3], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[4]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[5]. Prices may vary based on dose and promo availability.
| Provider | Starting Price | |
|---|---|---|
| Amazon One Medical | $25/mo | Visit |
| LillyDirect Foundayo | $25/mo | Visit |
| GoodRx | $149/mo | Visit |
| Kin Meds | $149/mo | Visit |
| PreventiveMD | $149/mo | Visit |
| Ro | $149/mo | Visit |
Foundayo Head-to-Head Comparisons
Short-form verdict pages comparing Foundayo to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.
See all drug-vs-drug verdicts.
Foundayo Patient Questions, Answered
Real patient questions about Foundayo pulled from named subreddits and answered with peer-reviewed trial data.
Foundayo Reference Cards
Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.
Related Research on Foundayo
Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.
Frequently Asked Questions
Sources & methodology — as of August 2026
- 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Glossary
The words sellers use, defined. Tap any term.
- Orforglipron · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism